Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer
Last Updated: Monday, October 12, 2026
RIBOLARIS is a phase II trial evaluating whether chemotherapy can be safely omitted in patients with stage II, grade 2/3 HR+ HER2- early breast cancer who convert to low genomic risk following neoadjuvant ribociclib plus letrozole.